For all new eyes: It is apparent that the current human

New Post Public Reply Private Reply Replies (4) Message Board
petemantx
1,530
For all new eyes:

It is apparent that the current human trial for Brilacidin in regards to CV19 is paramount to the success of IPIX, but for those not familiar with the IPIX story let's once again reiterate why Brilacidin is different from EVERY other drug going thru trials today and likely different from any drug EVER to go thru trials and why these differences are what makes every stockholder know that we are sitting on a gold mine with this stock:

1. Brilacidin was conceived by a medical genius, Dr. William DeGrado, who has published over 400 papers, won about every medical award that can be won, is the leading authority on the new arm of medicine that he brought into existence (that of defensin mimetics), and who currently runs his own lab strictly for defensin mimetic studies at the highly acclaimed UCSF, a public research facility associated with the U of CA system. UCSF has no undergraduate programs, every student there is working on advanced degrees and only gets accepted to work on a specific program. So all of Dr. DeGrado's graduates become proponents of his arm of medicine and further exploration of this arm of medicine. Dr. DeGrado is not a medical doctor, he is a phD specializing in pharmaceutical chemistry. This is why he was able to conceptualize the structure of the small molecule that would become Brilacidin.

2. Brilacidin was developed by humans (around 2002) but refined and improved by the closest thing to AI (artificial intelligence) as it spent about 6 years on the super computer (known as Big Ben) in Pittsburgh ramping up its benefits and eliminating its weaknesses which would lead to worrisome side effects. Compare this to all other drugs that went thru labs and one can understand why Brilacidin is seemingly light years ahead of its time.

3. Brilacidin has never failed a clinical trial and it has gone thru a number. It is anti viral, bacterial, fungal, inflammatory, and possesses unique immunotherapeutic properties and ALL of the above features are used to kill CV19. In these prior trials on over 400 patients it was also shown to be well tolerated with no discernible side effects (almost unheard of in todays pharma market, just listen to TV ads for drugs and one sees in most cases the side effects seem as dire as the problem it is supposed to cure).

4. Being that it kills viruses in a completely new way from all prior drugs, viruses cannot build up a resistance to it. Please note that Brilacidin KILLS the CV19 virus, a feature very few, if any, competitive products can claim.

5. In testing at government run regional bio labs (RBLs)IPIX had no input as to running the tests or interpreting the results)so all data was derived and published by those RBLs. It was shown to have a Selectivity Index (SI) of 426. This index evaluates the ability for in vitro testing (in a petri dish) to transfer with the same results in human testing. Anything over 100 is considered good and Remsdesivir received about a 129. Thus, it looks like Brilacidin should be a lock on working in humans as effectively as it did in petri dishes and on human tissues. To refresh your memory of human tissue results, Brilacidin killed 97% in lung tissue within a few hours and 85% in kidney tissues within a few hours. The IV being given in the current trial (I believe it is for about 1 hour but not positive) should help raise these numbers IMO as it keeps B in the system a decent amount of time.

6. Brilacidin is made from common materials, does not require special handling (as frigid cold as do other CV drugs/vaccines),is very cost effective compared to other methods, and is currently being developed for a nasal spray or nebulizer (sprayed directly into the lungs via the mouth)as additional delivery systems.

7. Brilacidin was shown to be so effective in the RBL testing that one requested funding for a PANCORONA investigation since it appears that Brilacidin could prove effective against ALL corona viruses to include The Flu and Herpes as just some of the other uses.

8. Brilacidin has yet to meet a bacteria or virus it couldn't kill.

The above points of fact, all derived by non-IPIX sources, should give all stockholders a feeling that what we own is extremely special. Each stockholder must come to their own conclusions as to the point at which they will sell their holdings in iPIX, but all should be aware that though this is currently a penny stock it is not because our products are not worth a FORTUNE and could very well lead to generational wealth in time for those that bet on this company early. I consider .45 still extremely early for all stockholders and hate to think some will be bamboozled to sell way too early and lose out on a possible golden ring stock that comes along only a few times in a lifetime.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 211

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 254

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 138

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 356

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 177

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 225

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading

Top 5 Most Recently Viewed Articles

Impressive Financial Growth for Caris Life Sciences in Q2 2025

Updated Category News Views 262

Caris Life Sciences Achieves Significant Growth in Financial Results Today, Caris Life Sciences, Inc. (NASDAQ: CAI) reported remarkable financial results, highlighting a 81.3% increase in total revenue year-over-year for the second quarter of 2025. This substantial growth showcases the company's resilience and innovative approach in the ever-evolving healthcare landscape....

Continue Reading
What to Expect from Globus Maritime's Upcoming Earnings Report

Updated Category News Views 253

Anticipating Globus Maritime's Earnings Report Globus Maritime (NASDAQ: GLBS) is gearing up to unveil its quarterly earnings report soon, and investors are eager to gain insight into the company’s financial performance. This report will be a crucial indicator of the company's trajectory as it navigates the ever-changing maritime industry. Analyst Expectations for...

Continue Reading
Discover Exciting Savings with Haoqi E-Bikes This Sale

Updated Category News Views 187

Haoqi E-Bikes Launches Exciting Black Friday Sale With a profound appreciation for family and the great outdoors, Haoqi E-Bikes is thrilled to reveal its noteworthy promotion on the highly sought-after Cheetah Dual Battery Full Suspension E-Bike. From an initial launch date, the brand will provide an incredible discount of $1101 on the Cheetah model to promote outdoor...

Continue Reading
3 Unstoppable Dividend Stocks for Income Investors

Updated Category News Views 125

Finding Reliable Dividend Stocks For investors seeking income, stocks that offer stability and dependable dividends are often the preferred choice. It's generally unwise to invest in companies with uncertain futures that might reduce their dividends. Instead, savvy investors focus on resilient dividend stocks that promise steady returns and growth over time. A Dividend...

Continue Reading
Certification Boosts Aviation Capital's Boeing 737-10 Prospects

Updated Category News Views 115

Nothing like a green light from the FAA to put a little extra swagger in an aircraft lessor's step, and that's exactly what's happening with Aviation Capital Group (ACG) and their big bet on Boeing's 737-10. It's like the champagne just got popped! This milestone is no minor hurdle. We're talking about the largest addition to the 737 MAX family finally giving an official...

Continue Reading